Nitrogen In Aglycone Moiety Patents (Class 536/17.9)
-
Publication number: 20140187499Abstract: The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same.Type: ApplicationFiled: November 13, 2013Publication date: July 3, 2014Inventors: Gérard SOULA, Emmanuel DAUTY, Richard CHARVET
-
Patent number: 8765692Abstract: Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.Type: GrantFiled: June 22, 2012Date of Patent: July 1, 2014Assignees: The Scripps Research Institute, The University of Chicago, Bringham Young UniversityInventors: Paul B. Savage, Luc Teyton, Albert Bendelac
-
Publication number: 20140179761Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.Type: ApplicationFiled: October 22, 2013Publication date: June 26, 2014Applicant: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
-
Patent number: 8759501Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.Type: GrantFiled: January 18, 2008Date of Patent: June 24, 2014Assignee: Genzyme CorporationInventors: Yunxiang Zhu, Seng H. Cheng, Canwen Jiang, Luis Z. Avila
-
Patent number: 8742079Abstract: Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates. Glycosylation reagents for use in preparing these conjugates are also disclosed. Glycosylated proteins, characterized by improved performance, are also disclosed.Type: GrantFiled: August 20, 2008Date of Patent: June 3, 2014Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer
-
Patent number: 8722864Abstract: The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs of the analgesic acetaminophen. This invention relates to a method for the production of a broad group of glycosides of acetaminophen derivatives.Type: GrantFiled: July 14, 2011Date of Patent: May 13, 2014Assignee: Nutek Pharma Ltd.Inventors: Brian Shull, John Baldwin, Ramesh Gopalaswamy, Zishan Haroon
-
Publication number: 20140128584Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.Type: ApplicationFiled: May 31, 2012Publication date: May 8, 2014Applicant: ARROWHEAD MADISON INC.Inventors: Andrei V. Blokhin, David B. Rozema, Jonathan D. Benson, Jeffrey C. Carlson
-
Publication number: 20140112975Abstract: L-Rhamnose antigen-lipid conjugates for recruitment of the immune system to sites of tumor growth for initiating an anti-tumor antigen response. Methods for introducing L-rhamnose antigen-conjugated lipids into cell membranes such that L-rhamnose antigens are displayed on the cell surface. The cells can be tumor cells and more specifically can be melanoma cells. Cells are contacted with one or more L-rhamnose antigen-lipid conjugates such that L-rhamnose antigen-lipid conjugates are inserted into the cell membrane. The cells can be contacted for example by intratumoral injection. Pharmaceutical compositions containing the L-rhamnose antigen-lipid conjugates and therapeutic methods employing the conjugates and compositions.Type: ApplicationFiled: March 15, 2013Publication date: April 24, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventor: WISCONSIN ALUMNI RESEARCH FOUNDATION
-
Patent number: 8703720Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3.Type: GrantFiled: April 26, 2010Date of Patent: April 22, 2014Assignee: Galecto Biotech ABInventors: Hakon Leffler, Ulf J. Nilsson, Henrik Von Wachenfeldt
-
Publication number: 20140107328Abstract: Chemoselective isolation of aliphatic hydroxyl group-containing and aromatic hydroxyl group-containing compounds is accomplished via formation of polymeric siloxyl ethers. Chemoselective release of aliphatic hydroxyl group-containing and aromatic hydroxyl group-containing compounds from polymeric siloxyl reagents is described.Type: ApplicationFiled: December 11, 2013Publication date: April 17, 2014Inventors: Erin E. CARLSON, Darci TRADER
-
Patent number: 8697659Abstract: The invention provides analogs of alpha-galactosyl ceramide that increase the immune response elicited by various antigens. It also provides methods of using such compounds to increase the effectiveness of vaccines.Type: GrantFiled: October 10, 2008Date of Patent: April 15, 2014Assignee: Luigi PanzaInventor: Luigi Panza
-
Patent number: 8685936Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.Type: GrantFiled: March 12, 2010Date of Patent: April 1, 2014Assignee: Apogee Biotechnology CorporationInventors: Charles D. Smith, Yan Zhuang, Lynn W. Maines
-
Patent number: 8685942Abstract: A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.Type: GrantFiled: April 5, 2011Date of Patent: April 1, 2014Inventors: Richard A. Gross, Mark H. Schofield
-
Publication number: 20140088297Abstract: New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent. an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP.Type: ApplicationFiled: September 13, 2013Publication date: March 27, 2014Applicant: Michigan Diagnostics, LLCInventors: Brij Pal Giri, Dinesh Dagli, Pritam Singh
-
Patent number: 8679854Abstract: The present invention relates to a fluorescent dye-labeled glucose analog, and a synthesis method and usage of the same, and more particularly, to novel glucose ? and ? anomers in which a fluorescent dye is labeled by O-1-glycosylation, an asymmetric synthesis method of the anomers, a molecular bioimaging method of the anomers, and a screening method of curing or preventing drugs for diseases related to glucose metabolism.Type: GrantFiled: December 21, 2007Date of Patent: March 25, 2014Assignee: SNU & DB FoundationInventors: Seung Bum Park, Myung Haing Cho, Hyang Yeon Lee, Jong Min Park
-
Publication number: 20140073594Abstract: Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: GlycoMimetics, Inc.Inventors: John L. Magnani, Arun K. Sarkar
-
Publication number: 20140066609Abstract: A novel synthesis method of Glyco-drug radiotracer precursor is revealed. After completing synthesis of Z-Gly-ah (main structure), galactosamine GalNAc(OAc)4 is added to have coupling reaction. Then a product is separated directly from dichloromethane. Thus loss of galactosamine during extraction with liquid chromatography is reduced. Moreover, instead of trifluoroacetyl group, carbobenzoxy (abbreviated as Cbz or Z) is used as a protecting group to ensure uniformity of the phase. The cost and synthesis time are also dramatically reduced.Type: ApplicationFiled: September 5, 2012Publication date: March 6, 2014Applicant: ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCHInventors: Kuei-Lin LU, Yu CHANG, Cheng-Fang HSU, Mei-Hui WANG, Wuu-Jyh LIN
-
Publication number: 20140050775Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: ApplicationFiled: March 8, 2013Publication date: February 20, 2014Applicant: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Publication number: 20140046045Abstract: A method for preparing a precursor used to label hepatocyte receptors is revealed. The precursor contains a bifunctional structure including trisaccharide and DTPA ligand. During synthesis processes of the precursor, silica gel columns and Reverse phase-18 (RP-18) columns are used for purification. Thus both the purification times and cost of each purification are reduced. Moreover, use diethyl ether to facilitate precipitation of products and remove a part of coupling reagent. Removing the coupling reagent helps purification of products. Furthermore, N?,N?-bis(carboxymethyl)-L-lysine hydrate and benzyl chloroformate are coupled to form a trisaccharide skeleton so as to ensure the yield rate of trisaccharide structure.Type: ApplicationFiled: August 10, 2012Publication date: February 13, 2014Applicant: ATOMIC ENERGY COUNCIL - INSTITUTE OF NUCLEAR ENERGY RESEARCHInventors: CHIH-YUAN LIN, YU CHANG, JEN-TSUNG WANG, CHENG-FANG HSU, WEI-TI KUO, HUNG-WEN YU, WUU-JYH LIN, MEI-HUI WANG
-
Publication number: 20140045779Abstract: This invention relates with anti-tumor activities of new compounds containing an adamantyl group or analogs thereof.Type: ApplicationFiled: August 29, 2011Publication date: February 13, 2014Inventor: Lifeng Xu
-
Publication number: 20140037693Abstract: This invention relates to galactosylceramide compounds.Type: ApplicationFiled: May 20, 2013Publication date: February 6, 2014Applicants: The Scripps Research Institute, The University of Chicago, Brigham Young UniversityInventors: Paul B. SAVAGE, Albert BENDELAC, Luc TEYTON
-
Patent number: 8642565Abstract: The present invention relates to compounds consisting of glycolipids covalently bound to an antigen or a drug via a linker. The said compounds are able to induce a stronger immune response than a composition comprising separated glycolipids and antigen. The said compounds are also able to target drug to CD1d restricted cells.Type: GrantFiled: November 7, 2008Date of Patent: February 4, 2014Assignee: WittycellInventor: Vincent Serra
-
Publication number: 20140024816Abstract: A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.Type: ApplicationFiled: September 19, 2013Publication date: January 23, 2014Inventors: Richard A. Gross, Mark H. Schofield
-
Patent number: 8624006Abstract: The present invention provides a one-pot method of preparing an unprotected ?-O-glycolipid. The first step involves contacting a protected ?-iodo sugar with a catalyst and a lipid comprising a hydroxy group, under conditions sufficient to prepare a protected ?-O-glycolipid. The second step involves deprotecting the protected ?-O-glycolipid under conditions sufficient to prepare the unprotected ?-O-glycolipid, wherein the contacting and deprotecting steps are performed in a single vessel. The present invention also provides a one-pot method of preparing an unprotected ?-O-glycolipid following the steps for the preparation of the unprotected ?-O-glycolipid.Type: GrantFiled: April 8, 2008Date of Patent: January 7, 2014Assignee: The Regents of the University of CaliforniaInventors: Jacquelyn Gervay-Hague, Wenjun Du, Suvarn S. Kulkarni, Matthew Schombs
-
SUBSTITUTED AROMATIC COMPOUND, HYDROGELATION AGENT, HYDROGEL, AND METHOD FOR GELATING AQUEOUS SAMPLE
Publication number: 20140005279Abstract: According to the present invention, a substituted aromatic compound represented by the following general formula (I) is provided. In general formula (I), A1, A2, and A3 each independently represent an aryl group substituted by a hydrophilic group.Type: ApplicationFiled: March 9, 2012Publication date: January 2, 2014Applicants: NISSAN CHEMICAL INDUSTRIES, LTD., NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITYInventors: Masamichi Yamanaka, Daisuke Higashi -
Publication number: 20130345411Abstract: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.Type: ApplicationFiled: August 20, 2013Publication date: December 26, 2013Applicants: MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.Inventors: Yoshihiko KOBAYASHI, Yoshihisa AKIYAMA, Takeshi MURAKAMI, Nobuto MINOWA, Masaki TSUSHIMA, Yukiko HIRAIWA, Shoichi MURAKAMI, Mitsuhiro ABE, Kazushige SASAKI, Shigeru HOSHIKO, Toshiaki MIYAKE, Yoshiaki TAKAHASHI, Daishiro IKEDA
-
Publication number: 20130331556Abstract: A catalytic glycosylation method comprising: installing thioether to an anomeric carbon of a carbohydrate; and catalytically activating the thioether with a non-oxophilic Lewis acid. The thioether may comprise an anomerically stable thioether leaving group. The catalytic glycosylation method may further comprise: utilizing an acid-sensitive ester protecting group as permanent protecting group or using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process. A protecting group to mask hydroxyl functionalities in the production of oligosaccharides, natural products or any molecule having a hydroxyl group comprising an acid-labile ester protecting group.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventor: Xinyu Liu
-
Publication number: 20130331280Abstract: The disclosure relates to labeling glycans and glycosphingolipids from undefined mixtures with chemical moieties that emit light when exposed to electromagnetic radiation and uses of these labeled glycans and glycosphingolipids in microarrays for research and diagnostic purposes. In certain embodiments, the disclosure relates to derivatizing glycosphingolipids with a marker.Type: ApplicationFiled: November 22, 2011Publication date: December 12, 2013Applicant: EMORY UNIVERSITYInventors: Richard D. Cummings, David F. Smith, Xuezheng Song
-
Publication number: 20130324707Abstract: The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be used to aid the isolation of membrane proteins, for example, to aid their solubilization and/or purification. The compounds can also be used to aid the functional and structural determination of membrane proteins, including their stabilization and crystallization.Type: ApplicationFiled: August 7, 2013Publication date: December 5, 2013Applicants: The Board of Trustees of the Leland Stanford Junior University, Wisconsin Alumni Research FoundationInventors: Samuel Helmer GELLMAN, Pil Seok CHAE, Brian KOBILKA, Soren RASUMSSEN
-
Patent number: 8586051Abstract: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.Type: GrantFiled: March 15, 2012Date of Patent: November 19, 2013Assignees: The Rockefeller University, The Scripps Research InstituteInventors: Moriya Tsuji, David D. Ho, Chi-Huey Wong, Douglass Wu, Masakazu Fujio, Xiangming Li
-
Publication number: 20130288992Abstract: Compounds of formula (I?) wherein: R11, R12, R13, R14 and R15 are hydrogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-carbonyloxy, or a G-O— group, and at least one of R11, R12, R13, R14 and R15 is a G-O— group, wherein G is a saccharide residue, X1 is a single bond, or a methylene group, an ethylene group, a trimethylene group, a vinylene group or —CH?CH—CH2—, X2 is —CO—O— or —O—CO—, p and q are integer ofs 0 to 7, and p+q=0 to 8, Y1 is methylene, ethylene or an alkenylene group having a carbon number of 2 to 15 and 1 to 3 double bonds, and R16 and R17 are hydrogen, methyl or ethyl, or R16 and R17 form a C3-6 cycloalkyl group, are useful as GLP-1 secretion promoting agents.Type: ApplicationFiled: June 21, 2013Publication date: October 31, 2013Inventors: Wataru KUROSAWA, Takuya Toyoda, Risa Ubagai, Yoshihito Nogusa, Kana Oyama, Yusuke Amino
-
Patent number: 8551959Abstract: The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like.Type: GrantFiled: March 25, 2009Date of Patent: October 8, 2013Assignee: RIKENInventors: Takuya Tashiro, Kenji Mori, Masao Shiozaki, Ryusuke Nakagawa, Masaru Taniguchi, Hiroshi Watarai
-
Patent number: 8552163Abstract: This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilotriacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in N?-benzyloxycarbonyl-N?-dicarboxymethyl-L-lysine can be conjugated with three glycosides of ahGalNAc or ahLac in one step. This invention also provides a hexa-lactoside. In particular, the TFA-AHA-Asp was used to conjugate 2 molecules of NTA(ahLac)3. This invention also provides a method for adding a spacer between NTA and DTPA. The extended hepatocyte-specific glyco-ligand has higher 111In-radiolabelling yield than those non-extended.Type: GrantFiled: September 27, 2010Date of Patent: October 8, 2013Assignees: Johns Hopkins University, Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: Reiko Takasaka Lee, Yuan-Chuan Lee, Mei-Hui Wang, Wuu-Jyh Lin
-
Publication number: 20130260402Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: ApplicationFiled: March 13, 2013Publication date: October 3, 2013Inventors: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., The United States of America as represented by the Secretary of the Department of Health and Human
-
Publication number: 20130261067Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.Type: ApplicationFiled: March 12, 2013Publication date: October 3, 2013Inventors: Vanessa RAGAGLIA, Vandana Madanlal Sharma
-
Publication number: 20130252268Abstract: The present invention relates to the visualization of acidic organelles based upon organelle enzyme activity. The organelle substrates of the invention are specific for enzyme activity of the organelle and label these organelles, such as lysosomes, rendering them visible and easily observed. Substrates of the present invention include substrates that produce a fluorescent signal. The fluorogenic acidic organelle enzyme substrates of this invention are designed to provide high fluorescence at low pH values and are derivatized to permit membrane permeation through both outer and organelle membranes of intact cells and can be used for staining cells at very low concentrations. They can be used for monitoring enzyme activity in cells at very low concentrations and are not toxic to living cells or tissues.Type: ApplicationFiled: May 14, 2013Publication date: September 26, 2013Applicant: Marker Gene Technologies, Inc.Inventors: John J. Naleway, Daniel J. Coleman
-
Patent number: 8536140Abstract: A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.Type: GrantFiled: December 13, 2010Date of Patent: September 17, 2013Assignee: MTI Meta Tech Inc.Inventors: Michael Thomas Clandinin, Eek J. Park
-
Publication number: 20130237489Abstract: A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5? position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.Type: ApplicationFiled: November 17, 2011Publication date: September 12, 2013Applicant: Technion Research & Development Foundation LimitedInventors: Timor Baasov, Dana Atia-Glikin, Jeyakumar Kandasamy, Valery Belakhov
-
Patent number: 8530631Abstract: The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be used to aid the isolation of membrane proteins, for example, to aid their solubilization and/or purification. The compounds can also be used to aid the functional and structural determination of membrane proteins, including their stabilization and crystallization.Type: GrantFiled: March 24, 2010Date of Patent: September 10, 2013Assignees: Wisconsin Alumni Research Foundation, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Samuel Helmer Gellman, Pil Seok Chae, Brian Kobilka, Soren Rasmussen
-
Publication number: 20130217640Abstract: The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs of the analgesic acetaminophen. This invention relates to a method for the production of a broad group of glycosides of acetaminophen derivatives.Type: ApplicationFiled: July 18, 2011Publication date: August 22, 2013Inventors: Brian Shull, John Baldwin, Ramesh Gopalaswamy, Zishan Haroon
-
Publication number: 20130217639Abstract: The present invention provides a compound selected from compound of formula (I), pharmaceutically acceptable salts of compound of formula (I), and pharmaceutically acceptable prodrugs of compound of formula (I), and a composition comprising the compound of the above and a pharmaceutically acceptable excipient. The present invention also provides a method for preparing a compound that activates natural killer T cells.Type: ApplicationFiled: February 22, 2012Publication date: August 22, 2013Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Chung-Shan Yu, Li-Wu Chiang, Kai-Hsiang Chang, Kuo-Yen Liao, Wen-Chin Su, Yin-Cheng Huang
-
Patent number: 8497361Abstract: An aminocoumarin conjugated to a fluorescent label through a secondary amine, is operative as a fluorescent polarization probe of the DNA gyrase B or topoisomerase IV E subunit. The probe is used for detecting topoisomerase inhibitor binding by fluorescence polarization, particularly in a high-through put topoisomerase inhibitor assay.Type: GrantFiled: August 22, 2011Date of Patent: July 30, 2013Assignee: SRI InternationalInventors: Peter Madrid, Bryan Glaser, Jeremiah Malerich
-
Publication number: 20130190257Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: Garnet BioTherapeutics, Inc.Inventor: Garnet BioTherapeutics, Inc.
-
Publication number: 20130190475Abstract: The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk1, Alk2, and W are as defined and described herein.Type: ApplicationFiled: July 22, 2011Publication date: July 25, 2013Applicant: SMARTCELLS, INC.Inventors: Zhiyu Chen, Thomas M. Lancaster, Todd C. Zion
-
Patent number: 8476414Abstract: An inventive substrate is provided which includes a substrate compound of formula A—B1—B2—B3: wherein A is a sugar moiety; B1 is a linker moiety allowing the conjugation of moiety A and the remaining structure of the substrate; B2 contains a permanently charged element such as a quaternary ammonium group so as to increase proton affinities and ionization efficiencies for mass spectrometry detection efficiencies analysis; and B3 of various carbon length conferring specificities to targeted enzymes. Also provided is a process to detect lysosomal diseases by contacting a sample with the inventive substrate along with an internal standard which is isotope-labeled analog of the product cleaved by a targeted enzyme upon the substrate.Type: GrantFiled: September 15, 2008Date of Patent: July 2, 2013Assignee: PerkinElmer Health Sciences, Inc.Inventor: Blas Cerda
-
Publication number: 20130165397Abstract: The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.Type: ApplicationFiled: September 12, 2011Publication date: June 27, 2013Applicants: ETH ZURICH, UNIVERSITY OF ZURICHInventors: Erik Boettger, Andrea Vasella
-
Publication number: 20130149259Abstract: A novel saccharide siloxane copolymer is useful in personal care compositions. The saccharide siloxane copolymer may be used as a universal emulsifier to prepare low odor emulsions for personal care applications.Type: ApplicationFiled: August 15, 2011Publication date: June 13, 2013Applicant: DOW CORNING CORPORATIONInventors: Cindy Delvalle, Eric Jude Joffre, Concettina Scavuzzo, Simon Toth, Isabelle Van Reeth
-
Patent number: 8461122Abstract: The disclosure relates to derivatives of morphine-6-glucuronide of formula (I) wherein R1 is as defined in the disclosure, or an acid addition salt thereof, as well as in hydrate or solvate form. The disclosure also relates to the preparation method thereof and to the use of same in therapeutics.Type: GrantFiled: June 8, 2011Date of Patent: June 11, 2013Assignee: SanofiInventors: Alain Dlubala, Claire Trecant, Isabelle Ripoche
-
Publication number: 20130130276Abstract: The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing ?1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom.Type: ApplicationFiled: May 17, 2011Publication date: May 23, 2013Applicants: School Juridical Person Kitasato Institute, Tokyo Institute of TechnologyInventors: Katsuko Yamashita, Keiko Fukushima, Masahiko Watanabe, Keishi Yamashita
-
Patent number: RE44778Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: May 30, 2012Date of Patent: February 25, 2014Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst